Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine.

Implementation science Integrated care Opioid agonist therapies (OAT) Opioids People who inject drugs (PWID) Ukraine

Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
10 Sep 2024
Historique:
received: 22 05 2024
revised: 28 08 2024
accepted: 09 09 2024
medline: 13 9 2024
pubmed: 13 9 2024
entrez: 12 9 2024
Statut: aheadofprint

Résumé

Ukraine has high HIV prevalence, concentrated among people who inject drugs (PWID), mostly of opioids. Maintenance on opioid agonist therapies (OAT) is the most effective evidence-based treatment for opioid use disorder. As PWID experience high morbidity and mortality from preventable and treatable non-communicable diseases, international agencies recommend integrating OAT into primary care centers (PCC). A randomized, type-2 hybrid implementation trial was carried out to compare outcomes of OAT integration in PCC to OAT delivery at specialty treatment centers (STC) - standard-of-care. Tele-education supporting PCC providers in managing OAT, HIV, tuberculosis and non-communicable diseases along with pay-for-performance incentives were used to facilitate implementation. Consenting patients underwent 1:2 randomization to either STC or PCC. Quality health indicators (QHIs), a composite percentage of recommended primary and specialty services accessed by patients (blood/urine tests, cancer screenings, etc.), were defined as efficacy outcomes and were assessed by participant self-report at baseline and every 6 months over 24 months and electronic chart reviews after the completion of the follow-up. The primary outcome is defined as the difference in composite QHI scores at 24 months, in which a repeated measures likelihood-based mixed model with missing at random assumptions will be used. Providers at PCC completed surveys at baseline, 12 and 24 months to assess implementation outcomes including changes in stigma and attitudes towards OAT and PWID. Among the 1459 participants allocated to STC (N = 509) or PCC (N = 950), there were no differences in clinical and demographic characteristics. Self-reported prevalences were available for HIV (42 %), HCV (57 %), and prior tuberculosis (17 %). Study retention at 6, 12, 18, and 24 months was as 91 %, 85 %, 80 %, and 74 %, respectively. PWID have a high prevalence of medical comorbidities and integrating OAT into primary care settings has the potential to improve the health of PWID. Findings from this study can help guide implementation of integrated care in Ukraine and throughout similar low-resource, high-burden countries in the Eastern European and Central Asian region.

Identifiants

pubmed: 39265780
pii: S1551-7144(24)00273-8
doi: 10.1016/j.cct.2024.107690
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107690

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Eteri Machiavariani (E)

Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States of America. Electronic address: eteri.machavariani@yale.edu.

Kostyantyn Dumchev (K)

Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.

Iryna Pykalo (I)

European Institute of Public Health Policy, Kyiv, Ukraine.

Myroslava Filippovych (M)

Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.

Roman Ivasiy (R)

Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States of America.

Denise Esserman (D)

Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT, United States of America.

Lynn M Madden (LM)

Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States of America; APT Foundation, New Haven, CT, United States of America.

Daniel J Bromberg (DJ)

Department of Social and Behavioral Sciences, Yale School of Public Health, Yale University, New Haven, CT, United States of America; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States of America.

Marwan Haddad (M)

Center for Key Populations, Community Health Center Inc, Middletown, CT, United States of America.

Olga Morozova (O)

Department of Public Health Sciences, University of Chicago, Chicago, IL, United States of America.

Bachar Ahmad (B)

Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States of America.

David Oliveros Gómez (DO)

Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States of America.

Scott O Farnum (SO)

APT Foundation, New Haven, CT, United States of America.

Sergii Dvoriak (S)

Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.

Frederick L Altice (FL)

Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States of America; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States of America; Division of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America.

Classifications MeSH